Overview
ODTX market data
Price History
ODTX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.15 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.10 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -3,822.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $15.10 – $23.03 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1.1B · P/S 217.71.
Company News
JP Morgan Maintains Overweight on Odyssey Therapeutics, Raises Price Target to $29Benzinga · Aug 7, 2026, 4:15 PM
Odyssey Taps Evotec's AI-Driven Discovery Platform To Advance Autoimmune, Inflammatory Disease ProgramsBenzinga · Aug 6, 2026, 6:53 AM
8-K filing — Odyssey Therapeutics, Inc. (ODTX)SEC EDGAR · Aug 4, 2026, 11:00 AM
Oppenheimer Reiterates Outperform on Odyssey Therapeutics, Maintains $40 Price TargetBenzinga · Jun 18, 2026, 5:05 PM
Odyssey Therapeutics Q1 EPS $(6.77) Misses $(1.13) EstimateBenzinga · Jun 17, 2026, 9:00 PM
Cantor Fitzgerald Initiates Coverage On Odyssey Therapeutics with Overweight RatingBenzinga · Jun 2, 2026, 2:56 PM
TD Cowen Initiates Coverage On Odyssey Therapeutics with Buy RatingBenzinga · Jun 2, 2026, 2:55 PM
Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30Benzinga · Jun 2, 2026, 1:11 PM
JP Morgan Initiates Coverage On Odyssey Therapeutics with Overweight Rating, Announces Price Target of $26Benzinga · Jun 2, 2026, 1:04 PM
This Oppenheimer Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jun 2, 2026, 1:03 PM